Clinical trials: completed, sponsored by Janssen Research & Development, LLC
Healthy
A Study of JNJ-77474462 in Healthy Participants
The purpose of this study is to assess the pharmacokinetics (PK) of JNJ-77474462 after single subcutaneous (SC) or intravenous (IV) administrations and the effect of formulation concentrations on PK of JNJ-77474462 in healthy…
- Trial name
- NCT04544813
- Testing
- JNJ-77474462, Anakinra
- Where
- Australia
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants
The purpose of the study is to assess what drug does to body when healthy Chinese participants receive single oral dose of JNJ-77242113.
- Trial name
- NCT05703841
- Testing
- JNJ-77242113
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Adenomatous Polyposis Coli
A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
The purpose of this study is to determine the effect of JNJ-64251330 in participants with Familial Adenomatous Polyposis (FAP) on colorectal polyp burden (sum of the polyp diameters).
- Trial name
- NCT05014360
- Testing
- JNJ-64251330
- Where
- 16 sites in United States, France and 5 more
- Volunteers
- 42 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
The purpose of this study is to assess the bioequivalence of four different lazertinib oral tablet formulations in healthy adult participants under fasted condition.
- Trial name
- NCT05742594
- Testing
- Lazertinib
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Colitis, Ulcerative
A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis
The purpose of this study is to evaluate the pharmacokinetics (what the body does to the study medication) and safety of subcutaneously (under the skin) administered golimumab in pediatric participants (aged 2 to 17 years) with…
- Trial name
- NCT01900574
- Testing
- Golimumab
- Where
- 27 sites in United States, Austria and 8 more
- Volunteers
- 35 people
- Sponsor
- Janssen Research & Development, LLC
Neoplasms
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors
The purpose of this study is to determine the recommended phase 2 dose (RP2D) regimen(s) of JNJ-78306358 in Part 1 (Dose Escalation) and to determine the safety of JNJ-78306358 at the RP2D regimen(s) in Part 2 (Dose Expansion).
- Trial name
- NCT04991740
- Testing
- JNJ-78306358
- Where
- 5 sites in Israel, Spain
- Volunteers
- 39 people
- Sponsor
- Janssen Research & Development, LLC
Urothelial Cancer, Receptors, Fibroblast Growth Factor
A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations
The purpose of this non-interventional study is to identify participants with urothelial cancer (UC) and selected fibroblast growth factor receptor (FGFR) aberrations through molecular testing of their archival tumor tissue.
- Trial name
- NCT03955913
- Testing
- Archival Tumor Tissue Sample
- Where
- 199 sites in United States, Argentina and 12 more
- Volunteers
- 3,679 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of JNJ-64251330 in Healthy Participants
The purpose of this study is to evaluate: systemic and local gut (rectum and sigmoid colon) exposure to JNJ-64251330, local tissue Pharmacodynamics (PD) using gut (rectum and sigmoid colon) biopsies (Part 1) and the effect of…
- Trial name
- NCT04552197
- Testing
- JNJ-64251330, Tofacitinib
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Neoplasms
A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors
The main purpose of this study are to determine the recommended Phase 2 dose (RP2D) regimen and the maximum tolerated dose, and to determine the safety of JNJ-63898081.
- Trial name
- NCT03926013
- Testing
- JNJ-63898081
- Where
- 7 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants
The purpose of this study is to evaluate the single-dose pharmacokinetic (PK) and bioequivalence of Darunavir (DRV) in the presence of Cobicistat (COBI) when administered as a DRV/COBI fixed dose combination (FDC) tablet…
- Trial name
- NCT05378906
- Testing
- DRV/COBI FDC, COBI, DRV
- Where
- Belgium
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of JNJ-80202135 in Healthy Chinese Adult Participants
The purpose of this study is to assess the pharmacokinetic (PK) of nipocalimab following single intravenous (IV) administration in healthy Chinese participants.
- Trial name
- NCT05151692
- Testing
- Nipocalimab
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Neoplasms
A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors
The primary purpose of the study is to determine the recommended Phase 2 dose (RP2D) and schedule of JNJ-64457107 when administered intravenously (IV) to participants with advanced stage solid tumors in Part 1 and to further…
- Trial name
- NCT02829099
- Testing
- JNJ-64457107
- Where
- 4 sites in Israel, Spain
- Volunteers
- 95 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of Lazertinib (JNJ-73841937) in Healthy Participants
The purpose of this study is to evaluate the effect of steady-state concentrations of lazertinib on the single-dose pharmacokinetics (PK) of probe substrates (midazolam, rosuvastatin, and metformin) in healthy adult participants.
- Trial name
- NCT05076877
- Testing
- Lazertinib, Midazolam, Rosuvastatin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 9 years.
- Trial name
- NCT01517802
- Testing
- Abiraterone acetate, Prednisone
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa
A Study of Bermekimab in Patients With Hidradenitis Suppurativa
Phase 2 study of bermekimab in patients with moderate to severe Hidradenitis Suppurativa.
- Trial name
- NCT03512275
- Testing
- Bermekimab Monoclonal Antibody 400 mg
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Janssen Research & Development, LLC
Castration-Resistant Prostatic Neoplasms
A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the safety of the combination of cetrelimab, with apalutamide and to define a population of participants with metastatic castration-resistant prostate cancer (mCRPC) who respond to…
- Trial name
- NCT03551782
- Testing
- Cetrelimab 480 mg, Apalutamide 240 mg
- Where
- 34 sites in United States, Belgium and 5 more
- Volunteers
- 33 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of JNJ-64300535 in Healthy Participants
The purpose of this study is to evaluate the cellular immunogenicity of 3 monthly electroporation-mediated intramuscular (IM) injections of JNJ-64300535 in healthy participants.
- Trial name
- NCT04736147
- Testing
- JNJ-64300535
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study Exploring the Use of Challenge Agents in Healthy Volunteers or Participants With a Disease of Interest
The purpose of this study is to characterize the biological response in vivo to challenge agents (vaccines, antigen, drug, or mechanical challenges); to assess the safety and tolerability of the challenge agent and to…
- Trial name
- NCT05007756
- Testing
- UVB Challenge
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
The purpose of this study is to evaluate the efficacy and safety of ustekinumab in pediatric participants aged greater than or equal to (>=) 6 through less than (<) 12 years with moderate to severe chronic plaque psoriasis
- Trial name
- CADMUS Jr (NCT02698475)
- Testing
- Ustekinumab 0.75 mg/kg, Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- 31 sites in United States, Belgium and 7 more
- Volunteers
- 44 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses
The purpose of the study is to assess the safety and tolerability of JNJ-77474462 following single subcutaneous (SC) administration to healthy participants of Japanese descent.
- Trial name
- NCT04544826
- Testing
- JNJ-77474462
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC